TY - JOUR
T1 - Moclobemide treatment in multiple sclerosis patients with comorbid depression
T2 - An open-label safety trial
AU - Barak, Yoram
AU - Ur, Erel
AU - Achiron, Anat
PY - 1999
Y1 - 1999
N2 - Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patients with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.
AB - Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patients with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.
UR - http://www.scopus.com/inward/record.url?scp=0032958929&partnerID=8YFLogxK
U2 - 10.1176/jnp.11.2.271
DO - 10.1176/jnp.11.2.271
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 10334000
AN - SCOPUS:0032958929
SN - 0895-0172
VL - 11
SP - 271
EP - 273
JO - Journal of Neuropsychiatry and Clinical Neurosciences
JF - Journal of Neuropsychiatry and Clinical Neurosciences
IS - 2
ER -